$4.86
0.83% yesterday
Nasdaq, Jun 27, 10:00 pm CET
ISIN
US81728J1097
Symbol
SRTS

Sensus Healthcare, Inc. Stock price

$4.86
+0.04 0.83% 1M
-2.35 32.59% 6M
-2.06 29.77% YTD
-0.38 7.25% 1Y
-3.39 41.09% 3Y
+1.71 54.29% 5Y
-0.99 16.92% 10Y
-0.99 16.92% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+0.04 0.83%
ISIN
US81728J1097
Symbol
SRTS
Sector

Key metrics

Basic
Market capitalization
$79.9m
Enterprise Value
$60.9m
Net debt
$-19.1m
Cash
$19.1m
Shares outstanding
16.5m
Valuation (TTM | estimate)
P/E
44.18 | 17.14
P/S
2.02 | 1.83
EV/Sales
1.54 | 1.40
EV/FCF
13.14
P/B
1.51
Financial Health
Equity Ratio
89.80%
Return on Equity
11.91%
ROCE
4.78%
ROIC
3.84%
Debt/Equity
0.00
Financials (TTM | estimate)
Revenue
$39.5m | $43.6m
EBITDA
$3.0m | $3.3m
EBIT
$2.6m
Net Income
$1.8m | $4.7m
Free Cash Flow
$4.6m
Growth (TTM | estimate)
Revenue
24.73% | 4.32%
EBITDA
-47.57% | -61.81%
EBIT
-52.94%
Net Income
-61.29% | -29.92%
Free Cash Flow
200.65%
Margin (TTM | estimate)
Gross
56.02%
EBITDA
7.64% | 7.46%
EBIT
6.48%
Net
4.56% | 10.69%
Free Cash Flow
11.72%
More
EPS
$0.11
FCF per Share
$0.28
Short interest
5.57%
Employees
54.00
Rev per Employee
$770.00k
Show more

Is Sensus Healthcare, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Sensus Healthcare, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Sensus Healthcare, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Sensus Healthcare, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Sensus Healthcare, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
39 39
25% 25%
100%
- Direct Costs 17 17
38% 38%
44%
22 22
16% 16%
56%
- Selling and Administrative Expenses 14 14
35% 35%
35%
- Research and Development Expense 5.90 5.90
69% 69%
15%
3.02 3.02
48% 48%
8%
- Depreciation and Amortization 0.46 0.46
44% 44%
1%
EBIT (Operating Income) EBIT 2.56 2.56
53% 53%
6%
Net Profit 1.80 1.80
61% 61%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Sensus Healthcare, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sensus Healthcare, Inc. Stock News

Neutral
Business Wire
2 days ago
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company...
Neutral
Seeking Alpha
about one month ago
Sensus Healthcare, Inc. (NASDAQ:SRTS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Tirth Patel - Alliance Advisors, IR Joe Sardano - Chairman and CEO Michael Sardano - President & General Counsel Javier Rampolla - Chief Financial Officer Conference Call Participants Yi Chen - H. C. Wainwright Jason Wittis - Roth Capital Jeremy Pearlman - Maxim Group Ben Haynor ...
Neutral
Business Wire
about one month ago
BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three months ended March 31, 2025. Highlights of the first quarter of 2025 include the following: Rev...
More Sensus Healthcare, Inc. News

Company Profile

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+ and SRT-100 Vision. Its main product, superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Head office United States
CEO Joseph Sardano
Employees 54
Founded 2010
Website sensushealthcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today